Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16004961 | 0.85 | ALDH2 (0.33) | ALDH2KCNA3KDM1AKDM1BKDM4E | |
| SCHEMBL19584837 | 0.72 | F2RL1 (0.43) | ALDH2KCNA3F2RL1 | |
| SCHEMBL5986722 | 0.68 | KCNA3 (0.36) | KCNA3KDM4EALDH1A1HSD17B10 | |
| SCHEMBL6305402 | 0.67 | HTR2A (0.32) | KCNA3 | |
| SCHEMBL6304529 | 0.65 | ALDH2 (0.32) | ALDH2 | |
| SCHEMBL16005005 | 0.64 | PTPN1 (0.47) | POLB | |
| SCHEMBL16004954 | 0.64 | — | — | |
| SCHEMBL13725473 | 0.64 | KCNA3 (0.39) | KCNA3KDM4EALDH1A1HSD17B10 | |
| SCHEMBL12689887 | 0.64 | HDAC1 (0.37) | KDM1AKDM1BALDH1A1HPGD | |
| SCHEMBL850836 | 0.64 | KDM1A (0.50) | KDM1AKDM1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045545-B1 | Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists | ELI LILLY AND COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-6967201-B1 | for increasing activation of the 5-HT2C receptor in mammals; treatment of depression, obesity, bulimia, premenstrual syndrome, alcoholism, tobacco abuse, panic disorder | ELI LILLY AND COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| US-6881733-B1 | Serotonergic benzofurans | ELI LILLY AND COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1204659-B1 | SEROTONERGIC BENZOFURANS | LILLY CO ELI (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1204654-B1 | BENZOFURYLPIPERAZINES: 5-HT2C SEROTONIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2003-07-23 | — | — | EP | disclosed |